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Biomaterials, especially those based on nanomaterials, have emerged as critical tools in biomedical applications. The applications
encompass a wide range such as implantable devices, tissue regeneration, drug delivery, diagnostic systems, andmolecular printing.
The type of materials used also covers a wide range: metals (permanent and degradable), polymers (permanent and degradable),
carbon nanotubes, and lipid nanoparticles. This paper explores the use of microfluidic platforms as a high-throughput research
tool for the evaluation of nanobiomaterials. Typical screening of such materials involves cell/tissue cultures to determine attributes
such as cell adhesion, proliferation, differentiation, as well as biocompatibility. In addition to this, other areas such as drug
delivery and toxicity can also be evaluated via microfluidics. Traditional approach for screening of such materials is very time-
consuming, and a lot of animals should be sacrificed since it involves one material and a single composition or concentration for
a single test. The microfluidics approach has the advantage of using multiple types of drugs and their concentration gradients
to simultaneously study the effect on the nanobiomaterial and its interaction with cell/tissue. In addition to this, microfluidics
provides a unique environment to study the effect of cell-to-extracellular interaction and cell-to-cell communication in the
presence of the nanobiomaterials.
1. Introduction
The field of microfluidics has seen great advances in the past
decade. Two important application areas of microfluidics
have been the use of it as a platform for medical diagnostics
and biosensing. Microfluidic platforms like lab-on-a-chip
have the advantage of using very small quantities of reagents,
typically in the nanoliter to microliter range. This feature
is very valuable in medical diagnoses like cell-based assays,
drug screening, and screening for diseases [1–9]. Microflu-
idic devices are especially useful for cell-based assays because
of the comparable scale of microfluidic channels and cells. In
addition to this, the scale of the devices allows for things like
growth factors to accumulate and form a stable environment
for cell culture. Microfluidics also presents the potential to
influence stem cell research, particularly for high-throughput
analysis of signals that affect stem cells [4]. In light of this
potential, one of the leading areas for microfluidics research
will be its use as a platform for nanobiomaterials-based
cell cultures [1–6, 10–20]. Such a high-throughput method
will be a key factor in the future in enabling more realistic
predictions of nanobiomaterial behavior in relation to cell
toxicity, cell proliferation, and differentiation. This predictive
capability is very important for preclinical methods since
this has a direct impact on improving the attrition rates of
candidate materials during clinical testing [21, 22].
This paper reviews the use of microfluidics as a high-
throughput analysis platform for evaluation of nanobioma-
terials. First, we provide a brief overview of microfluidic
devices and their advantages over traditional cell culture
technology. The following section discusses nanobiomate-
rials and some of their biomedical applications. Section 3
discusses the advances in microfluidic technology and how it
is being applied as a high-throughput method in areas such
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as material screening, toxicity testing, and drug discovery.
Finally, Section 4 reviews research performed in evaluating
nanobiomaterials using microfluidics. We conclude the
paper with suggestions for next steps in specific areas.
2. Overview of Nanobiomaterials and
Their Applications
Nanomaterials can provide the cells with the desiredmatrices
that mimic the native environment of the cells. Usage of
these materials includes hip replacements, fracture plates,
bioresorbable sutures, tissue engineering scaffolds, and drug
delivery devices [24–35]. Nanomaterials which mimic the
matrix composition of the body are important regulator of
stem cell differentiation towards specific cell lineages. These
materials provide sites for cell adhesion and initiation of
matrix-generated signal transduction pathways.
A nanobiomaterial can be defined as a biomaterial sub-
strate composed of nanometer scale components. One exam-
ple of a naturally occurring nanobiomaterial is inorganic
bone matrix which is composed of hydroxyapatite crystals.
Significant property changes can occur at the nanoscale,
especially related to surface energy and reactivity. There are
more atoms at the surface of nanostructured biomaterials
which results in a marked increase in surface area to
volume ratio when compared to micron scale biomaterials.
Correlations of surface properties with stability, toxicity, and
biodistributions are essential for in vivo applications [36].
This is very important considering that, for example, cell
adhesion, proliferation, and migration during tissue repair
are dependent on protein adsorption on the surface of
implanted biomaterials.
The application potential of nanobiomaterials varies
widely from tissue engineering to biosensing and diagnostics
to drug delivery and disease therapy. Examples of some
such applications are (a) nanohydroxyapatite for orthopedic
implants and drug carriers for bone diseases, (b) carbon
nanotubes and nanofibers as novel drug delivery devices, (c)
gold nanoparticles for cancer diagnostics, and (d) quantum
dots as biological sensors [37–43]. The use of carbon na-
notubes and various types of nanoparticles in medicine is
very prevalent in research and hence described in separate
sections here.
2.1. Carbon Nanotubes in Medicine. Carbon nanomaterials
are being used to develop the next generation of biomaterials
for applications in therapeutics and regenerative medicine.
Carbon nanomaterials, mainly in the form of nanotubes
and graphene, have become the focus of intensive research
because of their unique physical and chemical properties
such as their hollow structure, their high surface area-to-
volume ratio, electrical conductance, thermal conductivity,
mechanical stiffness, and the possibilities of functionalizing
them to change their intrinsic properties. Functionalization
can increase their solubility and biocompatibility under
physiological conditions. The nanomaterials can be further
conjugated with specific biomolecules such as polymers,
peptides, proteins, nucleic acids, and other therapeutic
agents, which can target specific types of cells, tissue, and
organs.
Carbon nanomaterials demonstrate several significant
features that have promise for use in nervous system
repair. Carbon nanomaterials have the type of nanosurface
features that have been demonstrated to encourage nervous
tissue regeneration, including the physical shape (a linear
geometry), the nanoscale surface topology, and the high
aspect ratio of nanomolecules or larger structures made
from carbon nanotubes, like carbon nanotube thread. These
closely resemble the microenvironment that nerve fibers
migrate along during embryonic development and regen-
eration. Carbon nanomaterials also offer high mechanical
strength to support process outgrowth and flexibility to
avoid further damage of soft surrounding tissues during
movement. Two applications of carbon nanomaterials of
especial interest to neurobiologists are discussed here, their
use in scaffolds to repair damaged nervous tissues, and
their use as biocompatible electrodes for recording from or
stimulating nervous tissues.
2.2. Nanoparticles in Medicine. Naturally occurring nano-
particles (NPs; such as LDL, HDL, and VDL), which
are endogenously produced in developed organism, are
utilized in transportation of hydrophobic molecules such as
cholesterol and triglycerides into various parts of the body
via the circulation. In the past twenty years, several groups
started to develop various nanoparticles that can be an
appropriate tool in diagnostics as well as cell/tissue-specific
therapy. At present, nanoparticles are applied in several
field of medicine: cancer treatment, high-resolution imaging,
siRNA-based gene therapy and so forth. In this section, we
give a brief summary on the up-to-date knowledge on NPs
used in medicine.
At the dawn of the application of nanometer-sized par-
ticles, liposomes, which encapsulated highly hydrophobic
anticancer agents (doxorubicin, daunorubicin), were used
to deliver these compounds via circulation to the tumor
cells. Due to passive distribution of these lipid vesicles in
the body, toxic side-effect might occur causing arrhythmia,
which could lead to heart failure. To overcome this problem,
active targeting of lipid vehicles has been extensively studied
and advanced: antibodies or their fragments, oligopeptides,
nucleic acids (aptamers), small molecules, or others (vita-
mins or carbohydrates) are conjugated to the surface of
nanoparticles [45].
In the presence of malignant tumors, hypocholesterole-
mia may arise due to the enhanced LDL uptake of cancerous
cells. Thus, LDL vesicles, as naturally targeted lipoprotein
vesicles, have been studied in diagnostics and treatment of
cancer for several years: (1) LDL particles loaded/conjugated
with photosensitizers are applied in photodynamic therapy;
(2) 99mTc, 131I, 125I, or 68Ga/111. In labeled LDLs were
used in in vivo tumor detection with gamma camera or
PET (positron emission tomography) in animal models,
respectively; (3) with the help of Gd or iron-loaded LDL
vesicles could adequately image the boundary of the tumor
with MRI [46–52]. It was also demonstrated that HDL
Journal of Nanomaterials 3
Cargo
DrugsiRNA, DNA
Targeting
AptamersAntibody Small molecule
Gd, 99mTc, Fe, QD
O
OO
O
OO
OH
OH
OH
OH
OH
H
NH2
Figure 1: Classification of lipid-based nanovesicles mainly used in medicine.
cholesterol level was lower in certainmalignancies, which can
be also attributed to increased cholesterol consumption of
cancer cells. Since several cancer cell lines express scavenger
receptor class B type I (SR-BI), which is responsible for HDL
uptake, anticancer agent loaded HDL or HDL mimicking,
targeted lipid-protein vesicles can be used to deliver their
cargo the tumor cells [53–55]. Furthermore, nanovesicles
can also be applied to boost the immune system: injections
of anticancer liposome vaccine resulted in hindered E.G7-
OVE tumor progression in mice, and, in a clinical study, the
survival time of patients with nonsmall cell lung cancer was
longer compared to control group [56–58].
Atherosclerosis is the chief risk factor in the onset of
cardiovascular diseases, which is a leading cause of death
in the adult population and characterized by a complex
etiology. In a recent paper, Lewis et al. reviewed several
novel, nanometer-sized particle approaches on the therapy
and detection of atherosclerotic plaques in model system or
in human (Figure 1) [59].
2.3. TiO2 Photocatalyst in Medicine. Biomedical research
applications of titania (TiO2) have primarily focused on
harnessing its potential as a photocatalyst, specifically its
ability to perform oxidative or reductive chemistry under
illumination of UV light [61, 62]. Recent advances in doping,
nanoparticle assembly, and dye conjugation have extended
this photochemistry into the visible [63, 64]. Applications
in biomedical field are becoming more routine due in part
to the use of titania as an implant material and a desire to
modify the surface of the titanium and make the implant
“smarter.” For example, photolysis of TiO2 and nanotube
TiO2 with X-ray radiation was performed to demonstrate a
possible drug release methodology [65]. In another study,
precursors to hydroxyapatite formation were embedded in
TiO2 nanotubes and shown to influence bone formation in
adult pig model [66]. Titania particles have also been used
in disinfection applications and the killing of cancer cells
[67, 68]. The ability to vary TiO2 properties, morphology,
and surface functionalities as a result of years of materials
research allows for a wide range of possible medical benefits.
3. Microfluidics Devices for High-Throughput
Analysis of Nanobiomaterials
There are numerous parameters of nanobiomaterials that
can affect cellular behavior. The complexity of interacting
parameters is one of the main motivations for the high-
throughput screening of nanobiomaterials.
3.1. Introduction to Microfluidics. Microfluidic devices that
enable high-throughput analysis have typically been pro-
duced using photoassisted and soft lithography techniques.
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Figure 2: (a) The geometry of a microfluidic cell culture array for high-throughput analysis, (b) cross-section of cell culture microchamber
[23] (reprinted from [23]).
An increasing demand for fully automated and quantitative
cell culture technology has resulted in the development
of microfluidic chip-based arrays. Compared to traditional
culture tools, microfluidic platforms provide much greater
control over cell microenvironment and rapid optimization
of media composition using relatively small numbers of cells.
Because a group of cells can more easily maintain a local
environment within microchannels than in traditional cul-
ture flasks, cells grow significantly slower in microchannels
than cells in traditional culture flasks [23, 70]. Figure 2 shows
a typical microfluidic cell culture array for high-throughput
analysis. The bonded PDMS cell culture microchambers
provide a stable and uniform microenvironment for the cells
[23].
3.2. Microfluidic Assays for Implant Material Screening.
Recent advances in microfluidic techniques have increased
the potential of high-throughput biochemical assays on
individual mammalian cells. A microfluidic assay for bac-
terial chemotaxis was developed, in which a gradient of
chemoeffectors was established inside a microchannel via
diffusion between parallel streams of liquid in laminar flow
[19, 71]. Bacterial adhesion often occurs in implant surgeries.
Biomaterial-related infection starts with the adhesion of
infectious bacteria, which is considered as one of the main
causes of failure in implant surgery. Bacterial adhesion to
surfaces is usually present in aqueous flows since such flows
can promote the transport of microorganisms to surfaces.
Considering that nanomaterial surfaces can be extremely
reactive, the problem of bacterial adhesion becomes even
more important. A microfluidic flow system was utilized to
investigate the behaviors of biological cells under various
flow conditions. This system offers precise kinetic control
of the cellular microenvironment [20]. Microfluidics can
also be applied for high-throughput and combinatorial
electrochemistry where numerous channels operating in
parallel can provide for synthesis of large arrays of materials
and subsequently characterized for corrosion properties
[44]. Figure 3 shows examples of such systems.
Microfluidic biochips offer the advantage of being able
to include a whole new set of technologies that can preserve
cellular function in vitro over a long period of time. This
in turn would allow the proposal of relevant and alternative
models to reduce the animal experimentation and their
costs. They offer the possibility of dynamic cultures and
kinetic studies on microengineered tissues simulating the
cellular organizations that are found in vivo. This would
minimize animal use as well as offer assays more relevant
than traditional techniques [73].
3.3. Microfluidics Screening in Tissue Engineering. Applica-
tions of microfluidic systems based on cell and tissue culture
are now emerging, as platforms for high-throughput screen-
ing, drug discovery, and toxicity testing. A new generation
of microfluidics-based approaches are designed for specific
tissue and organ applications, incorporating microvascular
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Figure 3: (a) Microfluidic assembly for high-throughput corrosion experiments, (b) multielectrode electrochemical testing cell [44]
(reprinted [44]).
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Figure 4: Organ-specific tissue-engineered microfluidic devices: (a) vasculature, (b) liver sinusoid, (c) renal tubule, and (d) alveolar fluid-
liquid interface [16] (reprinted from [16]).
networks, structures for transport and filtration, and a three-
dimensional microenvironment suitable for supporting phe-
notypic cell behavior, tissue function, and implantation,
and host integration [16]. Figure 4 shows a range of such
devices.
Microvascular networks are key sites for many of cell-
cell and particle-cell interactions during physiological and/or
pathological processes. Advances in targeted drug delivery
to the microvasculature often involve encapsulating drugs in
delivery vehicles ranging from microparticles to nanoparti-
cles. Development of in vitro microfluidic devices to mimic
these microcirculatory processes has been a critical step
forward in our understanding of the inflammatory process,
developing of nanoparticulate drug carriers, and developing
realistic in vitro models of the microvasculature and its
surrounding tissue [17].
3.4. Microfluidics with Microarrays for High-Throughput
Multiplexing. A microarray consists of a support onto which
hundreds to thousands of different molecular reporter
probes are attached or immobilized at fixed locations in
6 Journal of Nanomaterials
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Figure 5: (a) Layout of microfluidic gradient mixer used to generate a linear concentration gradient. (b) Linear concentration gradient
obtained from a three-dimensional numerical simulation using COMSOL. (c) Osteoblast cell live/dead assay using the microfluidic network
shown above.
either a two-dimensional or three-dimensional format. The
multiplexing capabilities of microarray-based assays are
produced by spatially encoding the array, in which each
location on the array is used as a reporter of a specific analyte.
For conventional microarrays, shortcomings include (a) the
analyte binding process on supports requires long incubation
times to produce the optimal signal due to slow diffusional
kinetics and (b) consumption of large amounts of precious
sample material for interrogating the array due to the large
area occupied by high-density arrays. The use of microfluidic
platforms can directly address these issues as well as offer the
potential for parallel processing of multiple samples [5].
Chemotaxis is the directional migration of cells in
response to chemical gradients of molecules called chemoat-
tractants. The process is crucial in numerous biological pro-
cesses. Most of the traditional methods (e.g., different types
of chambers or puffer pipettes) are nonideal in that the gen-
erated gradients are created in macroscopic environments,
are nonlinear, and change with time in an uncontrolled
manner. By making use of microfluidic gradient generators,
chemotaxis studies can be carried out with precise spatial
and temporal control of the chemical environment around
cells [6, 76]. Figure 5 shows an osteoblast cell live/dead assay
using a microfluidic gradient generator. Such a setup can be
used for screening of cell interaction with nanomaterials in
the presence of growth factors.
4. Evaluation of Nanobiomaterials
Using Microfluidics
4.1. Combinatorial Screening. The application of combina-
torial approaches to the discovery of new nanomaterials pro-
vides exciting opportunities to produce materials designed
to give optimal performance for specific applications. This
process has been facilitated by the development of the
automated fabrication and analysis of polymer microarrays,
produced largely by contact or ink-jet printing. Studies
have focused on the discovery of materials that support cell
attachment for particular cell types. In addition to appli-
cations of microarrays in screening for desirable material
properties, the size of the sample set provides enormous
potential to be able to elucidate key underlying principles
that govern biological-material interactions [2, 77–79]. As
mentioned previously in Section 2, the use of microfluidics
in conjunction with microarrays enables a high-throughput
mode for screening of nanomaterials and their interactions
with the cell environment.
Cell-based assays are currently considered central to
toxicity testing and biomaterials testing [6, 16, 81–86].
Despite the frequent lack of correlation between in vivo
models and in vivo observations, cell models still seek
validation as a useful screening bridge between materials
quality analysis and in vivo deployment. Advances in high-
throughput methods using microfluidics allow for toxicity
and efficacy screening of multiple nanomaterials at multiple
concentrations with multiple cell lines, simultaneously. By
assaying numerous material types/functionalizations and
material concentrations on numerous cell types, all in par-
allel, complex interactions between materials and cells may
be ascertained through data analysis [87]. Nanomaterials
for biomedical applications exhibit extremely high specific
surface areas exposed to physiological environments. Due
to the extremely reactive nature of nanomaterials surfaces,
extensive characterization and correlation of nanophase sur-
face properties with their stability, toxicity, and distributions
are essential for in vivo applications [36, 60].
One such study used surface chemistry, nanostructures,
and microfluidics to create a set of tools applicable for
problems ranging from molecular to cellular analysis. Mi-
crofluidics allows the precise manipulation of fluids down
to the nanoliter scale, and this is important since most
biochemical processes take place in the aqueous phase.
Surface gradients with arbitrary shapes from virtually any
type of biomolecules can be formed by transferring the
gradients in solution to a surface by adsorption as shown
in Figure 6 below. One example presented in this study is
that of axon specification during differentiation of neuritis
into axons and dendrites. Microfluidic gradient generators
similar to the one shown in Figure 6 were used to generate
gradients of laminin in solution and transferred to the
substrate by physical adsorption. The study indicates that
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Figure 6: (a) Generation of complex gradients in solution by com-
bining two microfluidic generators. (b) Transferring the gradient
in solution into a gradient on surfaces through adsorption [60]
(reprinted from [60]).
axon specification orients in the direction of increasing
laminin surface density [60].
4.2. Microfluidic Evaluation in Tissue Engineering. A micro-
fluidic 3D tissue model was used to evaluate the efficacy of
PLGA micropatterns for promoting osteogenic development
by osteoblasts and preventing biofilm formation. This study
demonstrated the tremendous efficiency of the tissue model
approach by significantly reducing the number of samples
and experiments required to assess the in vitro efficacy of
the micropatterns by conventional biofilm and cell culture
experiments. This approach provided an ability to directly
monitor how the 3D tissue development was positively
influenced by the presence of biphasic calcium phosphate
nanoparticles in the micropattern [15, 89]. Another study
looked at biofilm-related infection of orthopedic implants
in physiologically relevant microenvironments using a mul-
tichannel microfluidic device. It was used to observe in real
time the development of osteoblasts into three-dimensional
(3D) tissue-like structures how this development was influ-
enced by phenotypes of a specific bacteria [90]. The
microfluidics approach has also been used to build a three-
dimensional heterogeneous multilayer tissue-like structure
inside microchannels. Patterning of biological structures
can be achieved not only on the surface but also over the
thickness of the construct. The tissue formed from different
types of cells and biopolymer components can be engineered
to model layered in vivo living systems. This approach
provides a novel solution to fabricate hybrid biopolymers
and hierarchical tissue structures for tissue engineering and
basic cell biology [91]. One of the keys to tissue engineering
and cell therapy is the ability to identify materials that
support cell adhesion, proliferation, and differentiation.
One such study utilizes microfluidics for nanoliter-scale
synthesis of materials and simultaneous characterization of
their interaction with embryonic stem cells using this high-
throughput approach. This study simultaneously character-
izes over 1700 embryonic stem cell material interactions.
The identification of materials that selectively support the
growth of specific cell types could be useful for the creation of
complex tissue-engineered constructs. The proof-of-concept
study was carried out with hES cells, and it identified
polymers that allow for varying levels of hES cell attach-
ment and spreading, cell-type specific growth, and growth
factor-specific proliferation [92]. There are other studies
that discuss the characterization of biomaterial interaction
with stem cells using microfluidic approaches [3, 13, 93].
These approaches can be adopted for characterization of
nanobiomaterials as well.
Another study describes a highly parallel cell-based
microfluidic device where biomolecules are transported via
mobile substrates, like micro/nano beads or cells. Such
dynamic microarrays present several advantages over static
microarrays like the ability to mix andmatch the beads or the
cells to cater for the type of screening to be performed and
introduce them into the microarray on demand. The beads
or cells can be replaced, thus resulting in a reusable format
that greatly reduces the cost of operation. The reaction on
beads tends to be faster compared to conventional planar
surfaces, as micro/nano beads have increased surface area
to volume ratio and hence higher binding capacity. Com-
bining such a device with automation will allow for high-
throughput screening in an environment that closely mimics
cell-cell interactions found in animals [69]. Figure 7 shows
the potential contribution of MEMS and nanobiotechnology
to society.
4.3. Nanobiomaterials Evaluation for Diagnostics and Sen-
sors. A number of studies have focused on microfluidic
and nanofluidic devices as diagnostic tools for cancer
and other infectious diseases [29, 72, 94–97]. Inorganic
nanoparticles, semiconductor quantum dots (QDs), carbon
nanotubes, polymeric nanoparticles, as well as cantilevers
and nanochips, all have the potential to be useful in the
design of sensitive pathogen diagnostics [98]. The fabrication
of nanodevices as probes is complex, most likely the assem-
bly of building blocks including nanoparticles, nanowires,
nanotubes, and substrates. Typical examples of nanodevices
are nanofluidic arrays and protein nanobiochips. One of the
most promising uses of nanofluidic devices is isolation and
analysis of individual biomolecules, such as DNA, which
could lead to new detection schemes for cancer. Devices
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based on nanowires are emerging as a powerful and general
platform for ultrasensitive, direct electrical detection of
biological and chemical species [95]. Nanowire sensors may
be formed into dense circuits which can be constructed
within microfluidics environments, creating very dense sen-
sor libraries. These enable measurements of many different
genes and proteins from very small tissue samples or even
single cells [97]. Nano/microfluidic diagnostic technologies
are potentially applicable to global health applications, since
they are disposable, inexpensive, portable, and easy-to-use
for detection of infectious diseases. Nano/microfluidic tech-
nologies have been successfully integrated with current POC
devices for on-chip diagnosis and monitoring of infectious
diseases at resource-limited settings [72, 96]. Figure 8 shows
a microfluidic NMR biosensor combined with magnetic
nanoparticles.
Another study used microfluidics as an in vitro assess-
ment of the cytotoxicity potential of quantum dots. A mul-
ticompartmental device was integrated with a syringe pump
to establish a flow exposure system. This study enabled the
exposure of cell cultures to variable concentrations of QDs
simultaneously. The controlled flow conditions mimicked
in vivo physiological conditions very closely. The results
were compared to those from static exposure conditions.
Both static and flow conditions are illustrated in Figure 9
below. The static exposure of cells to QDs resulted in a
higher percentage of cell death and an increased number of
detached and deformed cells. This study demonstrated the
efficient utilization of microfluidic technology in nanotoxic-
ity research [74].
Another QD study involved tracking the mechanism of
nerve growth factor (NGF) signal propagation from the
axon terminal to cell body. Axonal transport of NGF signals
is critical to survival, differentiation, and maintenance of
peripheral sympathetic and sensory neurons. One set of
hypotheses for retrograde axonal transport of NGF states
that NGF and its signaling proteins are transported in
complex vesicles such as multivesicular bodies, lysosomes, or
macropinosomes. To study this, dorsal root ganglion (DRG)
neurons were cultured in a microfluidic chamber (shown in
Figure 10 below) and treated with quantum dot-labeled NGF
(QD-NGF). The conclusion from this study was that small
vesicles (50–150 nm) are responsible for most retrograde
axonal transport of QD-NGF in DRG axons [75].
In a third study involving QDs, an integrated microflu-
idic device capable of screening an anticancer drug has been
presented by analyzing apoptotic cells using biofunctional-
ized QDs. The cell immobilizing structures and gradient-
generating channels were integrated within the device. The
technique utilizes Annexin V conjugated quantum dots as
apoptosis detection probes as shown in Figure 11. This
technique can bridge the gap between the quantum dots
based in vitro cell imaging, and the analysis of individual
apoptotic cell in a microfluidic system allows an easy oper-
ating protocol to screen some clinically available anticancer
drugs [80].
Liposome nanoparticles have been evaluated for for-
mulation composition and stability using a microfluidic
biochip. Changes in size and surface chemistry of these
nanoparticles are important since they can significantly alter
in vivo distributions of these nanoparticles which affect
therapeutic outcomes. The biochip was embedded with
dielectric microsensors which enabled quantitative measure-
ments of formulation using unique electrical properties of
liposomes [99]. In another study, microfluidics has been
used as a platform for monitoring lipid vesicle membrane
permeability to tetracyclines. This approach allows for use of
artificial nanovesicles to study the influence on permeability.
Liposomes are immobilized onto the glass surface in a stripe
pattern via an avidin-biotin bond. The biggest advantage
provided by microfluidics in this case is the ability to reliably
resemble an in vivo environment. The fluid flow provides
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Figure 9: Schematic illustration of (a) static exposure resulting in
sedimentation of quantum dots and (b) flow exposure resulting in
homogeneous distribution of quantum dots [74] (reprinted from
[74]).
a constant concentration profile and thereby resembles the
drug transport via blood in the human body. Additionally,
many different drug concentrations and pH conditions can
be investigated in parallel with this approach. It allows the
measurements of slow and fast kinetics with a good temporal
resolution, requires only short measuring times, consumes
very small volumes of drug solution and vesicle suspension,
and allows sensitive detection at low concentrations using
TIRFmicroscopy [88]. Figure 12 shows the setup used in this
study.
Figure 10: A representative image of DRG neurons cultured inside
amicrofluidic device. Axons were able to extend across two columns
of microgrooves into the distal axon chamber [75] (reprinted from
[75]).
Synthesis of nanoscale lipid vesicles using microfluidic
channels has been studied where the device geometry and
flow rate have been used to influence the vesicle size. This
method enables a reliable control over vesicle size and homo-
geneity when compared to bulk liquid synthesis techniques
[100].
5. Conclusions and Future Work
In summary, the use of microfluidics as a platform for
biomedical research and applications is very widespread.
The specific use of microfluidic devices in conjunction
with nanobiomaterials is becoming an established method
for fast-throughput analysis in biomedical engineering. The
usage covers cell-based assays for toxicity and biocompatibil-
ity screening of materials, tissue engineering and cell therapy,
10 Journal of Nanomaterials
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Figure 11: Schematic drawing of (a) microfluidic gradient generator, (b) cell trapping on sand-bag structures, and (c) detection of apoptotic
cells immobilized on dam structures using Annexin V conjugated QDs [80] (reprinted from [80]).
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nerve regeneration, diagnostics and sensing for infectious
diseases and cancer biomarkers, and drug discovery. The
nanomaterials used in themicrofluidic environments present
a challenge to characterization due to their unique properties
and reactive nature, and this should be noted while perform-
ing future research. These microfluidic platforms have great
potential for integration into lab-on-a-chip type of devices
and providing point-of-care solutions.
Future work in this area by the authors will focus on
using microfluidics as an assessment tool for nanobioma-
terials in emerging research on degradable metallic bioma-
terials. The target applications for such materials include
Journal of Nanomaterials 11
craniofacial and orthopedic implants, nerve regeneration,
bone and bone-ligament fixation, and airway stents. One of
the objectives of the research will be to use computational
tools to complement experimental efforts in microfluidics.
For example, computational models can be used to predict
distribution of species such as growth factors in cell culture
chambers as a result of concentration gradient generation
in microfluidic networks. Additionally, these models can be
used to simulate various microenvironments in cell cultures
which in turn mimic in vivo conditions. Finally, microfluidic
platforms can be used to assess the effect of growth factors on
nanobiomaterial-cell interactions, and the high-throughput
capability can result in simultaneous assessment of multiple
concentrations in conjunction with various biomaterial
compositions.
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